Statins and the progression of age-related macular degeneration in the United States.

<h4>Purpose</h4>To study the effect of statin exposure on the progression from non-exudative to exudative age-related macular degeneration (AMD).<h4>Methods</h4>Retrospective cohort study of commercially insured patients diagnosed with non-exudative AMD (n = 231,888) from 200...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Cassie A Ludwig, Daniel Vail, Nitya A Rajeshuni, Ahmad Al-Moujahed, Tatiana Rosenblatt, Natalia F Callaway, Malini Veerappan Pasricha, Marco H Ji, Darius M Moshfeghi
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/07271a77698a4554bd865cfc52fe3329
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:07271a77698a4554bd865cfc52fe3329
record_format	dspace
spelling	oai:doaj.org-article:07271a77698a4554bd865cfc52fe33292021-12-02T20:18:47ZStatins and the progression of age-related macular degeneration in the United States.1932-620310.1371/journal.pone.0252878https://doaj.org/article/07271a77698a4554bd865cfc52fe33292021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0252878https://doaj.org/toc/1932-6203<h4>Purpose</h4>To study the effect of statin exposure on the progression from non-exudative to exudative age-related macular degeneration (AMD).<h4>Methods</h4>Retrospective cohort study of commercially insured patients diagnosed with non-exudative AMD (n = 231,888) from 2007 to 2015. Time-to-event analysis of the association between exposure to lipid-lowering medications and time from non-exudative AMD to exudative AMD diagnosis was conducted. Outcome measures included progression to exudative AMD, indicated by diagnosis codes for exudative AMD or procedural codes for intravitreal injections.<h4>Results</h4>In the year before and after first AMD diagnosis, 11,330 patients were continuously prescribed lipid-lowering medications and 31,627 patients did not take any lipid-lowering medication. Of those taking statins, 21 (1.6%) patients were on very-high-dose lipophilic statins, 644 (47.6%) on high-dose lipophilic statins, and 689 (50.9%) on low-dose lipophilic statins. We found no statistically significant relationship between exposure to low (HR 0.89, 95% CI 0.83 to 1.38) or high-dose lipophilic statins (HR 1.12, 95% CI 0.86 to 1.45) and progression to exudative AMD. No patients taking very-high-dose lipophilic statins converted from non-exudative to exudative AMD, though this difference was not statistically significant due to the subgroup size (p = .23, log-rank test).<h4>Conclusions</h4>No statistically significant relationship was found between statin exposure and risk of AMD progression. Interestingly, no patients taking very-high-dose lipophilic statins progressed to exudative AMD, a finding that warrants further exploration.Cassie A LudwigDaniel VailNitya A RajeshuniAhmad Al-MoujahedTatiana RosenblattNatalia F CallawayMalini Veerappan PasrichaMarco H JiDarius M MoshfeghiPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 8, p e0252878 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Cassie A Ludwig Daniel Vail Nitya A Rajeshuni Ahmad Al-Moujahed Tatiana Rosenblatt Natalia F Callaway Malini Veerappan Pasricha Marco H Ji Darius M Moshfeghi Statins and the progression of age-related macular degeneration in the United States.
description	<h4>Purpose</h4>To study the effect of statin exposure on the progression from non-exudative to exudative age-related macular degeneration (AMD).<h4>Methods</h4>Retrospective cohort study of commercially insured patients diagnosed with non-exudative AMD (n = 231,888) from 2007 to 2015. Time-to-event analysis of the association between exposure to lipid-lowering medications and time from non-exudative AMD to exudative AMD diagnosis was conducted. Outcome measures included progression to exudative AMD, indicated by diagnosis codes for exudative AMD or procedural codes for intravitreal injections.<h4>Results</h4>In the year before and after first AMD diagnosis, 11,330 patients were continuously prescribed lipid-lowering medications and 31,627 patients did not take any lipid-lowering medication. Of those taking statins, 21 (1.6%) patients were on very-high-dose lipophilic statins, 644 (47.6%) on high-dose lipophilic statins, and 689 (50.9%) on low-dose lipophilic statins. We found no statistically significant relationship between exposure to low (HR 0.89, 95% CI 0.83 to 1.38) or high-dose lipophilic statins (HR 1.12, 95% CI 0.86 to 1.45) and progression to exudative AMD. No patients taking very-high-dose lipophilic statins converted from non-exudative to exudative AMD, though this difference was not statistically significant due to the subgroup size (p = .23, log-rank test).<h4>Conclusions</h4>No statistically significant relationship was found between statin exposure and risk of AMD progression. Interestingly, no patients taking very-high-dose lipophilic statins progressed to exudative AMD, a finding that warrants further exploration.
format	article
author	Cassie A Ludwig Daniel Vail Nitya A Rajeshuni Ahmad Al-Moujahed Tatiana Rosenblatt Natalia F Callaway Malini Veerappan Pasricha Marco H Ji Darius M Moshfeghi
author_facet	Cassie A Ludwig Daniel Vail Nitya A Rajeshuni Ahmad Al-Moujahed Tatiana Rosenblatt Natalia F Callaway Malini Veerappan Pasricha Marco H Ji Darius M Moshfeghi
author_sort	Cassie A Ludwig
title	Statins and the progression of age-related macular degeneration in the United States.
title_short	Statins and the progression of age-related macular degeneration in the United States.
title_full	Statins and the progression of age-related macular degeneration in the United States.
title_fullStr	Statins and the progression of age-related macular degeneration in the United States.
title_full_unstemmed	Statins and the progression of age-related macular degeneration in the United States.
title_sort	statins and the progression of age-related macular degeneration in the united states.
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/07271a77698a4554bd865cfc52fe3329
work_keys_str_mv	AT cassiealudwig statinsandtheprogressionofagerelatedmaculardegenerationintheunitedstates AT danielvail statinsandtheprogressionofagerelatedmaculardegenerationintheunitedstates AT nityaarajeshuni statinsandtheprogressionofagerelatedmaculardegenerationintheunitedstates AT ahmadalmoujahed statinsandtheprogressionofagerelatedmaculardegenerationintheunitedstates AT tatianarosenblatt statinsandtheprogressionofagerelatedmaculardegenerationintheunitedstates AT nataliafcallaway statinsandtheprogressionofagerelatedmaculardegenerationintheunitedstates AT maliniveerappanpasricha statinsandtheprogressionofagerelatedmaculardegenerationintheunitedstates AT marcohji statinsandtheprogressionofagerelatedmaculardegenerationintheunitedstates AT dariusmmoshfeghi statinsandtheprogressionofagerelatedmaculardegenerationintheunitedstates
_version_	1718374207423774720

Statins and the progression of age-related macular degeneration in the United States.

Ejemplares similares